Rhythm Pharmaceuticals Stock
Rhythm Pharmaceuticals Stock
A loss of -1.010% shows a downward development for Rhythm Pharmaceuticals.
The stock is one of the favorites of our community with 37 Buy predictions and 1 Sell predictions.
With a target price of 117 € there is a slightly positive potential of 18.78% for Rhythm Pharmaceuticals compared to the current price of 98.5 €.
Our community identified positive and negative aspects for Rhythm Pharmaceuticals stock for the coming years. 3 users see the criterium "Worthwhile Investment for the next years" as a plus for the Rhythm Pharmaceuticals stock. On the other hand our users think that "General Risks" could be a problem in the future.
Pros and Cons of Rhythm Pharmaceuticals in the next few years
Pros
?
M***** P*******
?
G***** c******* t* c**********
?
B****
Cons
?
W********* I********* f** t** n*** y****
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Rhythm Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Rhythm Pharmaceuticals | -1.010% | 10.615% | 4.211% | 28.571% | 5.882% | 341.964% | 768.421% |
| Heron Therapeutics Inc. | 0.630% | -35.714% | -23.680% | -74.673% | -74.309% | -81.771% | -97.186% |
| Evolus Inc | -0.740% | 23.433% | 12.001% | 29.160% | 18.495% | -25.770% | -32.021% |
| Champions Oncology Inc | - | -2.242% | -15.340% | -14.510% | -24.828% | -22.832% | -50.455% |
Comments
Rhythm Pharmaceuticals (RYTM) had its price target raised by JPMorgan Chase & Co. from $145.00 to $146.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals (RYTM) had its price target raised by Citigroup Inc. from $142.00 to $143.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals (RYTM) had its price target raised by Royal Bank Of Canada from $141.00 to $155.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for RYTM provided by MarketBeat